Can We use the Electronic Health Record to Predict Risk for Postpartum Depression?
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
Toward a better framework for postmarketing reproductive safety surveillance of medications
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.
Optimizing Cognitive Behavioral Interventions for Perinatal Depression
A wide range of delivery options may be effective for addressing symptoms of depression in perinatal individuals, and could therefore be leveraged to expand access to treatments.
Prediction of Postpartum Depression: Take a Closer Look at Question 3 on the PHQ-9
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Treating Insomnia During Pregnancy: Is Trazodone Safe?
More study is needed regarding the safety of trazodone for the treatment of insomnia during pregnancy.
Weekly Roundup for October 27, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.